Section Arrow
RLMD.NASDAQ
- Relmada Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2025/06/03 23:27 EDT
Last
 0.6973
-0.0112 (-1.58%)
Day High 
0.71 
Prev. Close
0.7085 
1-M High
0.7689 
Volume 
221.28K 
Bid
0.69
Ask
0.71
Day Low
0.6802 
Open
0.6895 
1-M Low
0.3233 
Market Cap 
23.52M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.64 
20-SMA 0.52 
50-SMA 0.41 
52-W High 4.47 
52-W Low 0.2404 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.51/-2.76
Enterprise Value
23.52M
Balance Sheet
Book Value Per Share
0.68
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed:2025/06/03 23:27 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous systemdiseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment ofdepression and other potential indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.